Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy DOI Creative Commons

Asier Lizama-Muñoz,

Julio Plaza‐Díaz

Biomolecules, Journal Year: 2025, Volume and Issue: 15(5), P. 639 - 639

Published: April 29, 2025

Cancer remains one of the leading causes mortality worldwide, with a growing need for precise and effective treatments. Traditional therapies such as chemotherapy radiotherapy have limitations, including off-target effects drug resistance. In recent years, targeted emerged promising alternatives, aiming to improve treatment specificity reduce systemic toxicity. Among most innovative approaches, bispecific antibodies, nanobodies, extracellular vesicles offer distinct complementary mechanisms cancer therapy. Bispecific antibodies enhance immune responses enable dual-targeting cells, nanobodies provide superior tumor penetration due their small size, present novel platform RNA delivery. This work aims review analyze these three assessing current applications, advantages, challenges, future perspectives.

Language: Английский

Nanobody-based drug delivery systems for cancer therapy DOI
Lin Liu, Bin Tu, Yao Sun

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 381, P. 113562 - 113562

Published: Feb. 22, 2025

Language: Английский

Citations

0
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics DOI Creative Commons
Vaishali Verma,

N. D. Sinha,

A. Raja

et al.

mAbs, Journal Year: 2025, Volume and Issue: 17(1)

Published: April 9, 2025

Viral infections remain a significant global health threat, with emerging and reemerging viruses causing epidemics pandemics. Despite advancements in antiviral therapies, the development of effective treatments is often hindered by challenges, such as viral resistance emergence new strains. In this context, novel therapeutic modalities essential to combat notorious viruses. While traditional monoclonal antibodies are widely used for treatment several diseases, nanobodies derived from heavy chain-only have emerged promising "nanoscale warriors" against infections. Nanobodies possess unique structural properties that enhance their ability recognize diverse epitopes. Their small size also imparts properties, improved bioavailability, solubility, stability, proteolytic resistance, making them an ideal class therapeutics review, we discuss role antivirals various Techniques developing nanobodies, delivery strategies covered, challenges opportunities associated use therapies discussed. We offer insights into future nanobody-based research support managing

Language: Английский

Citations

0
Bispecific Antibodies, Nanobodies and Extracellular Vesicles: Present and Future to Cancer Target Therapy DOI Creative Commons

Asier Lizama-Muñoz,

Julio Plaza‐Díaz

Biomolecules, Journal Year: 2025, Volume and Issue: 15(5), P. 639 - 639

Published: April 29, 2025

Cancer remains one of the leading causes mortality worldwide, with a growing need for precise and effective treatments. Traditional therapies such as chemotherapy radiotherapy have limitations, including off-target effects drug resistance. In recent years, targeted emerged promising alternatives, aiming to improve treatment specificity reduce systemic toxicity. Among most innovative approaches, bispecific antibodies, nanobodies, extracellular vesicles offer distinct complementary mechanisms cancer therapy. Bispecific antibodies enhance immune responses enable dual-targeting cells, nanobodies provide superior tumor penetration due their small size, present novel platform RNA delivery. This work aims review analyze these three assessing current applications, advantages, challenges, future perspectives.

Language: Английский

Citations

0